Mecasermin (FDA-Approved IGF-1) Is Indicated for ~350–500 People Worldwide, Not TRT Patients
The FDA-approved formulation of IGF-1, Mecasermin, is approved only for a very small population (roughly 350–500 people worldwide) with a genetic condition called growth hormone insensitivity. The speaker emphasizes that TRT patients with AI-induced IGF-1 suppression do not have this condition, making off-label IGF-1 prescription in this context inappropriate.
Safety Warning: GH Peptides May Be Unnecessary If Estrogen Is Properly Managed on TRT
The speaker warns that patients on TRT who are also prescribed an aromatase inhibitor and then offered GH peptides should question the root cause. The proper intervention is optimizing the TRT protocol to keep estrogen in normal ranges rather than crushing it with an AI and then layering on peptides to compensate. The peptides treat a symptom of poor protocol management, not a true deficiency.
TRT Clinic Revenue Loop: AI-Induced IGF-1 Deficiency Used to Upsell GH Peptides
Clinics prescribe testosterone, then prescribe an aromatase inhibitor for elevated estrogen (rather than optimizing the TRT protocol), which crashes estrogen and consequently collapses IGF-1 production. The clinic then sells GH-releasing peptides (CJC-1295, Ipamorelin, Tesamorelin) or IGF-1 to resolve the deficiency they created. The speaker frames this as either ignorance of the mechanism or deliberate upselling.
Aromatase Inhibitors Collapse IGF-1 by Eliminating Estrogen Required for GH→IGF-1 Conversion
The liver converts growth hormone into IGF-1, and that conversion requires estrogen. When estrogen is crashed via an aromatase inhibitor (commonly prescribed alongside TRT), the hepatic pathway for IGF-1 production is shut down. This creates an iatrogenic IGF-1 deficiency that clinics then offer to treat with GH-releasing peptides.